Pfizer Inc. (NYSE:PFE) has achieved yet another significant milestone in developing a coronavirus vaccine. The company is closing in on full enrollment, highly needed to test the much-needed vaccine's effectiveness.
Pfizer Coronavirus Vaccine
The drug maker has already enrolled 42,000 people above 30,000 initially expected and close to the 44,000 target. The company was forced to increase the participants to 44,000 to increase the diversity in the trial and include young people as old as 16 years and those with pre-existing conditions.
In addition, nearly 36,000 volunteers have already received a second of the two-dose COVID-19 vaccine. Unlike other drugmakers, Pfizer is yet to register any adverse effects as part of the Phase 3 trials. AstraZeneca plc. (NASDAQ:AZN) was forced to pause trials after one of the participants developed a neurological condition. Johnson & Johnson (NYSE: JNJ) was also forced to halt trials after one of the volunteers developed an unknown illness.
Success in phase 3 trials without any substantial adverse effects would go a long way in helping Pfizer secure the vaccine's emergency use. The company is already planning to apply for authorization from the Food and Drug Administration.
Pfizer CEO, Albert Bourla, has already confirmed that no data on the trial results would be released until a week after the safety monitoring board conducts its review. Likewise, no vaccine would be made available before the election, as promised by President Donald Trump.
Disappointing Q3
The company needs emergency use authorization to strengthen its revenue base through vaccine sales. A disappointing third-quarter is already putting pressure on the company to succeed in the trials. In the recent quarter, sales were down by 4.3%, attributed to lower demand for the company’s products due to the pandemic.
Sales came in at $12.13 billion compared to $12.68 billion reported a year earlier. It also fell short of the $12.32 billion expected by Wall Street. However, profits topped Wall Street estimates, coming in at 72 cents a share against 71 cents that analysts were expecting.